Physician profile
Omer Ilyas
NPI 1922341890
$7,742.65
in general payments reported to CMS, 2019-2025
49 companies · $3,794 in 2025
The $3,794 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $220 · 2021: $135 · 2022: $395 · 2023: $959 · 2024: $1,939 · 2025: $3,794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,122 · Long Term Medical Supply Or Device Loan: $1,629 · Education: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.23 |
| Long Term Medical Supply Or Device Loan | $1,629.42 |
| Education | $940.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,019.46 | 2023-2025 | |
| Astellas Pharma US INC | $750.99 | 2020-2025 | Cresemba, Padcev, Xospata |
| E.R. Squibb & Sons, L.L.C. | $676.03 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $415.93 | 2019-2025 | Adcetris |
| Daiichi Sankyo INC. | $329.92 | 2023-2025 | Vanflyta, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $299.32 | 2023-2025 | Tagrisso, Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $250.99 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $241.95 | 2019-2023 | Lumakras |
| Exelixis INC. | $238.46 | 2023-2025 | Cabometyx |
| Lilly USA, LLC | $208.49 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $168.45 | 2023-2025 | |
| Genentech USA, INC. | $151.23 | 2022-2025 | Polivy, Phesgo, Tecentriq |
| Abbvie INC. | $142.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $131.60 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $126.76 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Ilyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.